Clinical Inquiries

Which detoxification regimens are effective for alcohol withdrawal syndrome?

Author and Disclosure Information

EVIDENCE-BASED ANSWER:

Benzodiazepines remain the first-line regimen for alcohol withdrawal syndrome (AWS) and are the only class more effective than placebo for reducing seizure (strength of recommendation [SOR]: B, based on 3 medium-quality randomized controlled trials [RCTs]). Anticonvulsants are no more effective than placebo at reducing seizures (SOR: B, based on 10 moderate-quality RCTs). Gabapentin reduces withdrawal symptoms and is less sedating than benzodiazepines (SOR: B, based on 1 medium-quality RCT). Carbamazepine also reduces withdrawal symptoms (SOR: B, based on 3 RCTs). Evidence of benzodiazepine superiority to other drugs with respect to safety is lacking (SOR: A, based on a meta-analysis).


 

References

EVIDENCE SUMMARY

Benzodiazepines work—but how do they compare?

A 2010 Cochrane meta-analysis of 64 RCTs and controlled clinical trials (CCTs; N = 4309) evaluated the use of benzodiazepines for treatment of AWS in adults.1 This systematic review compared benzodiazepines

  • vs placebo (10 studies)
  • vs other drugs, including phenobarbital, carbamazepine, topiramate, lamotrigine, gabapentin, haloperidol, clonidine, hydroxyzine, propranolol, and baclofen (42 studies)
  • to other benzodiazepines, including chlordiazepoxide, alprazolam, diazepam, and lorazepam (18 studies)
  • in combination with other drugs vs other drugs alone (3 studies)
  • administered on a fixed schedule vs symptom-triggered administration (3 studies).

Primary outcomes included efficacy (alcohol withdrawal seizures, alcohol withdrawal delirium, alcohol withdrawal symptoms, global improvement), safety (adverse events and severe, life-threatening adverse events), and acceptability (dropouts and dropouts due to adverse events).

Benzodiazepines performed better than placebo for seizures in 3 studies (N = 324), with a relative risk (RR) of 0.16 (95% confidence interval [CI], 0.04-0.69). Studies assessing the described outcomes between benzodiazepines and other drugs were often of small sample size and heterogeneous in ­interventions and outcomes, limiting the ability to draw clear conclusions regarding benzodiazepine superiority. Comparisons of different benzodiazepines with each other and comparisons of benzodiazepines combined with other drugs vs other drugs alone did not reach statistical significance. Data on harms of benzodiazepines were lacking.

Anticonvulsants are not better than placebo for AWS

Another 2010 Cochrane meta-analysis of 56 RCTs and CCTs (N = 4076) evaluated the use of anticonvulsants for AWS.2 This systematic review compared anticonvulsants

  • vs placebo (17 studies)
  • vs other drugs, such as bromocriptine, piracetam, gamma-hydroxybutyric acid, trifluoperazine, clonidine, and various benzodiazepines (32 studies)
  • to other anticonvulsants (10 studies)
  • in combination with other drugs vs other drugs alone (6 studies)
  • in combination with other drugs vs different anticonvulsants (1 study).

Primary outcomes included reductions in alcohol withdrawal seizures, adverse events, and acceptability of medication as indicated by participant dropouts.

Anticonvulsants were not superior to placebo for any outcome. Three studies (N = 260) favored carbamazepine over benzodiazepine (oxazepam or lorazepam) for 1 secondary outcome: a reduction of Clinical Institute Withdrawal Assessment of Alcohol Scale (CIWA-Ar) score (maximum score of 7; mean difference [MD] = –1 [95% CI, –1.9 to –0.2]).

Continue to: Gabapentin is effective; less sedating than chlordiazepoxide

Pages

Evidence-based answers from the Family Physicians Inquiries Network

Recommended Reading

Long-term CPAP use linked with more physical activity
MDedge Family Medicine
Home devices screen for atrial fibrillation
MDedge Family Medicine
Obesity pegged as diabetes cause in almost half of U.S. cases
MDedge Family Medicine
COVID-19 vaccination linked to less mechanical ventilation
MDedge Family Medicine
Armpit swelling after COVID-19 vaccine may mimic breast cancer
MDedge Family Medicine
Big data ‘clinch’ link between high glycemic index diets and CVD
MDedge Family Medicine
No vascular benefit of testosterone over exercise in aging men
MDedge Family Medicine
Rural women receive antibiotics for longer than necessary for UTIs
MDedge Family Medicine
ACIP recommendations for COVID-19 vaccines—and more
MDedge Family Medicine
14-year-old girl • history of bullying • lack of social support • multiple linear scars on breasts • Dx?
MDedge Family Medicine